Interní Med. 2015; 17(1): 42-44
Dapagliflozin - a new option in treating type 2 diabetes mellitus
- Interní klinika 2. LF UK a FN Motol
Dapagliflozin is a highly selective SGLT2 inhibitor. Following its administration, glucose reabsorption in the proximal tubule is decreased.
In individuals with diabetes, dapagliflozin reduces glycated haemoglobin by 0.5–0.8% in comparison with placebo, with its effect being
independent on the presence of insulin. Dapagliflozin reduces body weight, waist circumference, and the volume of both visceral and
subcutaneous fat. Dapagliflozin slightly decreases systolic blood pressure. In November 2012, dapagliflozin was registered for the treatment
of type 2 diabetes patients under the name Forxiga. The basic therapeutic dose is 10 mg of dapagliflozin. It is indicated as monotherapy
or combination therapy, including a combination with insulin. Genital fungal infections are the most common adverse effect.
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes mellitus
Published: February 27, 2015 Show citation
References
- Musso G, et al. A novel approach to kontrol hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44(4): 375-393.
Go to original source... 
Go to PubMed... - Kvapil M. Glifloziny: Inhibitory SGLT 2. In Kvapil M (eds) Diabetologie 2013. Triton, Praha 2013.
- Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol 2001; 280: F10-F18. Go to original source... Go to PubMed...
- Marks J, et al. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003; 553: 137-145. Go to original source... Go to PubMed...
- Asano T, Anai M, Sakoda H. SGLT as a therapeutic target. Drugs Fut 2004; 29: 461-466. Go to original source...
- Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2012; 46(4): 590-598. Go to original source... Go to PubMed...
- Meng W et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for thetreatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149. Go to original source... Go to PubMed...
- SPC - souhrn údajů o přípravku - Forxiga.
- Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012; 12(3): 230-238. Go to original source... Go to PubMed...
- Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res. 2012; 9(2): 117-123. Go to original source... Go to PubMed...
- Nauck MA, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9): 2015-2022. Go to original source... Go to PubMed...
- Chao EC. A paradigm shift in diabetes therapy-dapagliflozin and other SGLT2 inhibitors. Discov Med. 2011; 11(58): 255-263. Go to PubMed...
- Rosenstock J, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35(7): 1473-1478. Go to original source... Go to PubMed...
- Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3): 1020-1031. Go to original source... Go to PubMed...